STOCK TITAN

Annexon Inc - ANNX STOCK NEWS

Welcome to our dedicated news page for Annexon (Ticker: ANNX), a resource for investors and traders seeking the latest updates and insights on Annexon.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Annexon's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Annexon's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.15%
Tags
none
-
Rhea-AI Summary
Annexon, Inc. presented results from the ongoing ARCHER trial, showing ANX007's potential neuroprotective mechanism of action and consistent protection from vision loss in patients with geographic atrophy (GA). The drug demonstrated statistically significant protection from vision loss and was well-tolerated. Annexon plans to engage with regulatory agencies to determine the next steps for ANX007.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Annexon, Inc. has announced the appointment of Jamie Dananberg, M.D., as chief medical officer. Annexon is a biopharmaceutical company developing complement-based medicines for autoimmune, neurodegenerative, and ophthalmic disorders. Dr. Dananberg brings over 20 years of drug development experience to the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.82%
Tags
management
Rhea-AI Summary
ANNX to Present Results from ARCHER Phase 2 Trial at ASRS 2023 Annual Meeting, Host Investor Conference Call
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
conferences clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-59.38%
Tags
clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.46%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.57%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.95%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.77%
Tags
earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.19%
Tags
conferences
Annexon Inc

Nasdaq:ANNX

ANNX Rankings

ANNX Stock Data

561.22M
35.93M
0.5%
95.36%
3.18%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Brisbane

About ANNX

our mission is to develop disease-modifying therapeutics for patients suffering from neurological disorders such as huntington’s disease and alzheimer’s disease by targeting complement-mediated neurodegeneration (cmnd).